Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 4U54CA260563-02
Grant search
Key facts
Disease
COVID-19Start & end year
20202025Known Financial Commitments (USD)
$359,168Funder
National Institutes of Health (NIH)Principal Investigator
PROFESSOR Ignacio SanzResearch Location
United States of AmericaLead Research Institution
EMORY UNIVERSITYResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Individuals with multimorbidityOther
Occupations of Interest
Unspecified
Abstract
Abstract COVID-19 infection is greatly heterogenous. Individuals with underlying immune dysregulation, will have abnormal responses to COVID-19, thereby accounting for different short-term outcomes and memory formation. Specifically, emerging evidence indicates poor outcomes in autoimmune and cancer patients. We propose that autoimmune patients and severe COVID-19 infection will share an exacerbated pathological response while cancer patients with disease-associated or treatment-induced immune deficiency, will fail to mount a protective anti-viral response. Here, we shall interrogate the effector B cell response to SARS-CoV-2 to identify determinants of protective and pathogenic responses in HC and autoimmune subjects.